Peptides for Female Fertility — Evidence Review
Female fertility is the domain of reproductive endocrinology, with first-line interventions including ovulation induction (clomiphene, letrozole), assisted reproductive technology, and treatment of…
Female fertility is the domain of reproductive endocrinology, with first-line interventions including ovulation induction (clomiphene, letrozole), assisted reproductive technology, and treatment of underlying conditions (PCOS, endometriosis, premature ovarian insufficiency). Peptides are not first-line therapy and most are explicitly contraindicated in pregnancy and pre-pregnancy windows.
The evidence here is limited; this guide flags what's preliminary, what's contraindicated, and where to direct patient questions.
Peptides with research interest (not yet clinical)
Kisspeptin
Hypothalamic peptide regulating GnRH pulsatility and the HPG axis. Research interest in hypothalamic amenorrhea, IVF protocols, and fertility induction. Several Phase 1/2 studies report use as an alternative to hCG in IVF egg-trigger protocols, with potentially lower OHSS risk.
This is research-stage, not standard care. Reproductive endocrinology specialists are the right consultation.
Gonadorelin
Synthetic GnRH used in pulsatile delivery for hypothalamic amenorrhea and fertility induction in specific contexts. Has been used clinically in select cases of hypothalamic dysfunction with anovulation. Not a first-line therapy.
What the evidence does not support
- BPC-157, TB-500, or tissue-repair peptides for fertility
- GH secretagogues (CJC-1295, ipamorelin) for fertility outcomes — no controlled data
- GLP-1 agonists during pregnancy or pregnancy-planning windows — most have manufacturer-recommended washouts
- "Egg quality" peptide claims — outpace evidence
- Use as substitute for proper fertility workup
Critical safety considerations
Most peptides we cover lack pregnancy-safety data. Default position is avoid during pregnancy and breastfeeding. For patients planning pregnancy:
- GLP-1 agonists: manufacturer-recommended washouts vary (semaglutide ~2 months, tirzepatide ~1 month) before conception
- BPC-157, TB-500, and pro-angiogenic peptides: no pregnancy-safety data
- GH secretagogues: no pregnancy-safety data; pregnancy is generally considered a contraindication
Talk to a reproductive endocrinologist before any peptide therapy in fertility planning.
Where to source
Vendor data is limited for fertility-relevant peptides:
- Kisspeptin vendor rankings — limited
- Gonadorelin vendor rankings — limited
Most fertility peptide use happens within clinical research protocols, not consumer sourcing.
What we don't know
- Long-term outcomes of kisspeptin-triggered IVF cycles vs hCG-triggered
- Whether peptide therapy contributes to fertility outcomes in unexplained infertility
- Pregnancy and offspring safety for nearly all research-grade peptides
Methodology
Read the full methodology.
This page is educational. Fertility care should be directed by reproductive endocrinology specialists with access to your full reproductive history. Peptide therapy outside research protocols is not standard care for fertility.